Is it normal for the powder to not fully dissolve — my results so far

sarah.morrison said:

They are two different exemptions from the same federal requirements and they buy different things.

This is where I part company with the consensus forming above. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

FitDadDave said:

Two pharmacies quoted me last year, one describing itself as 503A and one as 503B, and I assumed 503B just meant bigger until both stopped within…

Compounded semaglutide formulations for compounded supply: some pharmacies add ingredients like B12, L-carnitine, or BPC-157 to their semaglutide preparations. Are these beneficial or marketing gimmicks?

My take: B12 addition has some logic (GLP-1s can deplete B12). L-carnitine evidence is weak. BPC-157 for GI protection is theoretically interesting but unproven. I prefer straight semaglutide with no additives — fewer variables, cleaner data on what's working.

SarahChen_PharmD said:

A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to.

Compounding pharmacy customer here with experience relevant to compounded supply.

I've ordered from 3 different compounding pharmacies over the past year. The quality variation is real — purity ranged from 94% to 101% of label claim based on independent Janoshik testing.

My current compounder (a 503B facility) has been consistently 98-101% purity across 6 orders. I pay $134/month vs $1,204 for brand. The savings are substantial and the product is equivalent in my experience.

Re: compounded supply — this applies whether you're using brand or compounded. The clinical principles are the same.

One thing that is still open after greg_boulder’s answer:

What actually distinguishes 503A from 503B, in terms of what each may make and from what starting material?

Reporting back.

The bulks-list asymmetry was the piece I had missed entirely. It explains why one of my two pharmacies is still arguing it can supply and the other simply stopped.